For instance, diclofenac, an inhibitor of MCT1 and MCT4, reprograms tumor glycolysis, reverses tumor acidification, and enhances the effectiveness of checkpoint therapy by promoting immune cell-driven anti-tumor responses [98]. This evidence concerns the gene SLC16A3 and neoplasm.